References in periodicals archive ?
cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Because of the well reported incidence of gross-hematuria and hemorrhagic cystitis in patients undergoing conditioning for allogeneic BMT/SCT, these patients are routinely prophylactically treated with continuous bladder irrigation (CBI), 2-mercaptoethanesulfonic acid (mesna), and hyperhydration during their myelosuppressive conditioning.
Demographic and clinical characteristics of study population and the chemotherapeutic agents n Chemotherapeutic agents Patients 28 Sex (M/F) 6/22 Age (years), 52.3[+ or -]9.6 mean[+ or -]SD Cancer related 22 Breast cancer 9 Vinorelbine, docetaxel, clodronate, ietrozole, trastuzumab, capecitabine paclitaxel, dexamethasone sodium phosphate, gemcitabine, cisplatin Colorectal cancer 7 5-FU, leucovorin oxaliplatin, cisplatin, docetaxel, bevacizumab, irinotecan Gastric cancer 2 5-FU, leucovorin, cisplatin, docetaxel Other malignancies Methotrexate, cytarabine, ifosfamide, mesna, etoposide Noncancer related 6 M, male; F, female; FU, fluorouracil.
[16] The drugs found to cause xerosis in this study were cyclophosphamide, carboplatin, ifosfamide, mesna and vincristine.
In general, it is known that the 5-year survival of patients with uterine carcinosarcomas receiving radiotherapy versus no irradiation was 41.5% and 33.2%, respectively.[7] A retrospective study assessed the efficacy and toxicity of a novel combination chemotherapy using carboplatin, ifosfamide, and mesna compared with other regimens for patients in adjuvant and palliative settings.
Protective effect of MESNA (2-mercaptoethane sulfonate) against hepaticischemia/reperfusion injury in rats.
Sodium-2-mercap-toethanesulphonate (MESNA), a sodium salt of 2-thiosulphonate anion, is now used for this purpose during otologic surgery; it provides more effective dissection because it cleaves the disulfide bonds [9].
Another study reported that these patients could undergo hematuria with increased chemotherapy toxicity because of DNA-repair defects despite the administration of the lower cyclophosphamide doses and the administration of the protective agent Mesna (Uromitexan; Eczacibasi-Baxter Medical, Istanbul, Turkey) (6).
She was well hydrated per protocol, but her cyclophosphamide regimen (3 g/[m.sup.2] of cyclophosphamide given in 1 g/[m.sup.2] doses) did not necessitate the use of mesna (10,11).
A total of 75 patients with severe scleroderma (diffuse cutaneous systemic sclerosis) underwent randomization to open-label treatment with either transplantation or intravenous cyclophosphamide at an initial dose of 500 mg/[m.sup.2] of body-surface area, followed by 11 monthly infusions of 750 mg/[m.sup.2] with mesna prophylaxis.
In the case of high risk of development of pulmonary hemorrhage, the VIP regimen (etoposide, mesna, ifosfamide, and cisplatin) could be chosen as first-line CT.